Novartis AG (NOVN)
SIX Swiss Exchange · Switzerland · prices in CHF · close of 22 Oct 2026
Key indicators
| Last close | CHF 128.88 |
|---|---|
| 52-week range | 97.05 – 132.68 |
| Return, 1 month / 3 months | +10.7% / +2.8% |
| Return, 1 year / 3 years | +26.6% / +68.3% |
| Trend | Uptrend |
| RSI (14) | 68 |
| Volatility (1 year) | 23.5% |
| Worst drawdown (1 year) | -15.0% |
| Average daily value traded | 355.75M CHF |
| Dividend yield | 2.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Novartis is a pharmaceutical company based in Basel, Switzerland. It develops and sells prescription medicines, with research and products focused on areas such as cancer, heart disease, immunology and eye care. Its customers are mainly hospitals, doctors and healthcare systems, and it also supplies generic and biosimilar medicines through its Sandoz division. The company operates research and manufacturing sites in several countries and serves patients in markets around the world.
On this site Novartis AG appears as a stock on the SIX Swiss Exchange (Switzerland), code NOVN, with prices in Swiss francs (CHF). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Novartis AG (NOVN) trades on the SIX Swiss Exchange in Switzerland. It last closed at CHF 128.88 on 22 October 2026.
Its price-based Market X-Ray is 71 out of 100 (a strong price profile), ranking 28 of 225 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 26.6% and over the last three months it rose 2.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on SIX Swiss Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 67 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 7.2% | ||
| From 52-week high | -1.9% | ||
| Momentum | 63 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 2.8% | ||
| 6-month return | 11.5% | ||
| 12-month return, skipping the last month | 14.4% | ||
| Stability (higher is calmer) | 73 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 23.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -15.0% | ||
| Liquidity | 100 · Strong | Trades actively. | |
| Average daily value traded | 355.75M CHF | ||
| Zero-volume days | 0.0% | ||
| Income | 60 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 2.9% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +2.4% |
|---|---|
| 1 month | +10.7% |
| 3 months | +2.8% |
| 6 months | +11.5% |
| 1 year | +26.6% |
| 3 years | +68.3% |
| 5 years | +111.9% |
Signals
| 50-day / 200-day average | 121.42 / 120.22 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.42 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 10 Mar 2026 | CHF 3.7000 |
| 11 Mar 2025 | CHF 3.5000 |
| 7 Mar 2024 | CHF 3.3000 |
| 9 Mar 2023 | CHF 3.2000 |
| 8 Mar 2022 | CHF 3.1000 |
| 4 Mar 2021 | CHF 3.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on SIX Swiss Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.